Extracellular vesicle therapeutics from plasma and adipose tissue

Iannotta, Dalila; Yang, Man; Celia, Christian; Marzio, Luisa Di; Wolfram, Joy

doi:10.1016/j.nantod.2021.101159

Cited by 40 publications

(38 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the size, the size-exclusion chromatography and tangential flow filtration are the most used. Based on exosome surface and immune affinity, CD63 and CD9 are the most used for their characterization [1,198,199] (Figure 2). Recently, developed technologies like the three-dimensional nanostructured microfluidic chip, using arrays of micropillars, were used to capture exosomes with high efficiency through a combination of a specific recognition molecule [18].…”

Section: Discussionmentioning

confidence: 99%

Exosomes and Micro-RNAs in Aging Process

2021

View full text Add to dashboard Cite

Exosomes are the main actors of intercellular communications and have gained great interest in the new cell-free regenerative medicine. These nanoparticles are secreted by almost all cell types and contain lipids, cytokines, growth factors, messenger RNA, and different non-coding RNA, especially micro-RNAs (mi-RNAs). Exosomes’ cargo is released in the neighboring microenvironment but is also expected to act on distant tissues or organs. Different biological processes such as cell development, growth and repair, senescence, migration, immunomodulation, and aging, among others, are mediated by exosomes and principally exosome-derived mi-RNAs. Moreover, their therapeutic potential has been proved and reinforced by their use as biomarkers for disease diagnostics and progression. Evidence has increasingly shown that exosome-derived mi-RNAs are key regulators of age-related diseases, and their involvement in longevity is becoming a promising issue. For instance, mi-RNAs such as mi-RNA-21, mi-RNA-29, and mi-RNA-34 modulate tissue functionality and regeneration by targeting different tissues and involving different pathways but might also interfere with long life expectancy. Human mi-RNAs profiling is effectively related to the biological fluids that are reported differently between young and old individuals. However, their underlying mechanisms modulating cell senescence and aging are still not fully understood, and little was reported on the involvement of mi-RNAs in cell or tissue longevity. In this review, we summarize exosome biogenesis and mi-RNA synthesis and loading mechanism into exosomes’ cargo. Additionally, we highlight the molecular mechanisms of exosomes and exosome-derived mi-RNA regulation in the different aging processes.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosomes and Micro-RNAs in Aging Process

2021

View full text Add to dashboard Cite

show abstract

“…Strategies to overcome such challenges include screening of donor MSCs for optimal growth capacity and stemness, the implementation of cell culture bioreactors, the use of scalable EV isolation methods, such as tangential flow filtration, and the use of cryoprotectants . Additionally, EV collection directly from fresh lipoaspirate or plasma can improve scalability by reducing costs and resulting in higher yields in shorter time periods compared to cell culture-derived EVs. − However, when using biofluids as a source material, isolation of optimal EV subpopulations with enhanced targeting and/or therapeutic effects may be necessary to avoid coadministration of EVs with pathological effects, such as pro-inflammatory , or malignant − properties.…”

Section: Advantages Of Vesicular and Polymeric Drug Delivery Systemsmentioning

confidence: 99%

Injectable Drug Delivery Systems for Osteoarthritis and Rheumatoid Arthritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Joint diseases are one of the most common causes of morbidity and disability worldwide. The main diseases that affect joint cartilage are osteoarthritis and rheumatoid arthritis, which require chronic treatment focused on symptomatic relief. Conventional drugs administered through systemic or intra-articular routes have low accumulation and/or retention in articular cartilage, causing dose-limiting toxicities and reduced efficacy. Therefore, there is an urgent need to develop improved strategies for drug delivery, in particular, the use of micro- and nanotechnology-based methods. Encapsulation of therapeutic agents in delivery systems reduces drug efflux from the joint and protects against rapid cellular and enzymatic clearance following intra-articular injection. Consequently, the use of drug delivery systems decreases side effects and increases therapeutic efficacy due to enhanced drug retention in the intra-articular space. Additionally, the frequency of intra-articular administration is reduced, as delivery systems enable sustained drug release. This review summarizes various advanced drug delivery systems, such as nano- and microcarriers, developed for articular cartilage diseases.

show abstract

“…The immunotherapeutic and biologic activities of convalescent plasma, in addition to antiviral antibodies, have been discussed in recent publications ( 15 – 19 ). In this regard, there has been a great interest in harnessing plasma content for extracellular vesicles (EV) including exosomes for the treatment of COVID-19 ( 20 , 21 ). EVs are ubiquitously produced by many cell types as membrane-bound extracellular vesicles of 30 to 150 nm in size.…”

Section: Introductionmentioning

confidence: 99%

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

et al. 2022

View full text Add to dashboard Cite

The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.

show abstract

Extracellular vesicle therapeutics from plasma and adipose tissue

Cited by 40 publications

References 107 publications

Exosomes and Micro-RNAs in Aging Process

Exosomes and Micro-RNAs in Aging Process

Injectable Drug Delivery Systems for Osteoarthritis and Rheumatoid Arthritis

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

Contact Info

Product

Resources

About